Neurocrine Biosciences, Inc. $NBIX Shares Bought by Atle Fund Management AB

Atle Fund Management AB increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.1% in the third quarter, Holdings Channel.com reports. The firm owned 102,625 shares of the company’s stock after buying an additional 14,233 shares during the quarter. Neurocrine Biosciences comprises approximately 5.6% of Atle Fund Management AB’s investment portfolio, making the stock its 3rd biggest position. Atle Fund Management AB’s holdings in Neurocrine Biosciences were worth $14,406,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. Eastern Bank acquired a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $27,000. Quent Capital LLC acquired a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $32,000. Finally, MAI Capital Management boosted its position in Neurocrine Biosciences by 101.2% during the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after buying an additional 165 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the transaction, the insider owned 43,405 shares in the company, valued at $6,929,608.25. The trade was a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 1,190 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total transaction of $184,557.10. Following the transaction, the director directly owned 6,239 shares in the company, valued at approximately $967,606.51. This represents a 16.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 80,266 shares of company stock worth $11,400,517 over the last ninety days. 4.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have issued reports on NBIX. Mizuho upped their price target on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Truist Financial reduced their price objective on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Stifel Nicolaus raised their target price on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada upped their price target on Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $174.25.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $136.06 on Friday. The company has a market cap of $13.57 billion, a P/E ratio of 32.55, a PEG ratio of 0.73 and a beta of 0.28. The stock has a 50 day simple moving average of $143.13 and a two-hundred day simple moving average of $140.26. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.